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Background: Down-modulation of the CD4 receptor is one of the hallmarks of HIV-1 infection and it is believed to
confer a selective replicative advantage to the virus in vivo. This process is mainly mediated by three viral proteins:
Env, Vpu and Nef. To date, the mechanisms that lead to CD4 depletion from the surface of infected cells during
HIV-1 infection are still only partially characterized. In this study, we sought to identify and characterize cellular host
factors in HIV-1-induced CD4 down-modulation.
Results: To identify host factors involved in CD4 down-regulation, we used a whole genome-targeting shRNA lentiviral
library in HeLa CD4+ cells expressing Nef as an inducer of CD4 down-modulation. We identified 55 genes, mainly
encoding for proteins involved in various steps of clathrin-mediated endocytosis. For confirmation and further selection
of the hits we performed several rounds of validation, using individual shRNA lentiviral vectors with a different target
sequence for gene knock-down in HIV-1-infected T cells. By this stringent validation set-up, we could demonstrate
that the knock-down of DNM3 (dynamin 3), SNX22 (sorting nexin 22), ATP6AP1 (ATPase, H+ Transporting, Lysosomal
Accessory Protein 1), HRBL (HIV-Rev binding protein Like), IDH3G (Isocitrate dehydrogenase), HSP90B1 (Heat shock
protein 90 kDa beta member 1) and EPS15 (Epidermal Growth Factor Receptor Pathway Substrate 15) significantly
increases CD4 levels in HIV-infected SupT1 T cells compared to the non-targeting shRNA control. Moreover, EPS15,
DNM3, IDH3G and ATP6AP1 knock-down significantly decreases HIV-1 replication in T cells.
Conclusions: We identified seven genes as cellular co-factors for HIV-1-mediated CD4 down-regulation in T cells. The
knock-down of four out of seven of these genes also significantly reduces HIV-1 replication in T cells. Next to a role in
HIV-mediated CD4 down-regulation, these genes might however affect HIV-1 replication in another way. Our findings
give insights in the HIV-1-mediated CD4 down-regulation at the level of the plasma membrane and early endosomes
and identify four possible new HIV-1 replication co-factors.
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The integral membrane protein CD4 is expressed in
hematopoietic cells, primarily on the surface of T-cell
progenitors, T helper cells and cells belonging to the
monocyte/macrophage lineage. In T lymphocytes this
protein acts as a co-receptor with the T-cell receptor
(TCR) for recognition of class II major histocompatibility* Correspondence: bruno.verhasselt@ugent.be
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unless otherwise stated.complex associated with antigenic peptide, participating in
T-cell development and activation. Following T-cell acti-
vation, CD4 is down-modulated via clathrin-mediated
endocytosis and is then sorted from early endosomes into
late endocytic organelles where it is degraded [1].
CD4 also serves as the primary receptor for HIV infec-
tion and CD4 down-regulation is an important determinant
of viral replication, pathogenesis and disease progression
[2-4]. HIV-mediated CD4 down-modulation can therefore
be considered as an interesting therapeutic target. Three
HIV-1 proteins are known to play a role in CD4 down-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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The development of multiple mechanisms for CD4
down-regulation by HIV points to the importance of
this phenomenon. Each of these proteins can reduce
CD4 surface expression independently and their con-
certed action is able to eliminate CD4 expression on
the surface of infected T cells almost completely [5,6].
The effect of Env on CD4 expression is mainly exerted
by the immature viral envelope complex gp160, which
retains the nascent CD4 molecules in the endoplasmic
reticulum (ER) [5,7]. The effects of Nef and Vpu are
quantitatively and qualitatively distinct. Nef acts on
CD4 expression early in the viral life cycle, enhancing
CD4 internalization from the cell surface by linking it
to the AP-2 clathrin adaptor [8,9]. Via its interaction with
β-COP, Nef appears to target the internalized receptor to
endosomes [10] and subsequently to the Multivesicular
Body Pathway (MVB) in an Endosomal Sorting Complex
Required for Transport (ESCRT)-dependent manner [11].
Vpu is expressed later in the life cycle of the HIV-1 virus
and causes the degradation of newly synthesized CD4
receptor, retained in the ER by the envelope glycoprotein
gp160. It has been shown that the Vpu-mediated degrad-
ation of CD4 happens via two independent mechanisms:
the viral protein can either trigger proteasomal degrad-
ation of the receptor by linking it to β-TrCP, a component
of the SCFβ-TrCP E3 Ub ligase complex [12]. Vpu can also
act in a variant Endoplasmic Reticulum-Associated Deg-
radation (ERAD) pathway to independently mediate the
retention of CD4 in the ER, a function traditionally attrib-
uted to Env [13-15]. However, the exact pathways used by
the HIV-1 proteins to divert the internalized CD4 mole-
cules to lysosomal degradation and hamper their recycling
remain to be identified.
Genome-wide RNA interference screenings are a useful
tool to discover the role of proteins in a given cellular
process. Several approaches have been described in which
libraries of short interfering RNAs (siRNAs) and short
hairpin RNAs (shRNAs) were used to identify new cellular
factors involved in HIV-1 infection and replication [16].
We chose to use a genome-wide shRNA screening to
identify new cellular factors involved in CD4 down-
modulation, using the expression of HIV-1 Nef as an
inducer of a rapid and efficient down-regulation of
CD4 from the cell surface in CD4-positive HeLa cells
(HeLa CD4++). In cells expressing a shRNA sequence
which blocks the expression of a gene involved in CD4
down-modulation, we expect high CD4 cell surface stain-
ing despite the expression of Nef. Positive hits selected
in this screening step were subsequently validated in a
HIV-1-infected T cell line to evaluate their role in HIV-
1-mediated CD4 down-modulation in a more relevant
model. To exclude off-target effects as much as possible,
validation of each positive hit was carried out usingdifferent shRNA targeting sequences compared to the
ones used in the screening. We identified seven genes
for which knock-down significantly rescued CD4
expression in HIV-1 infected SupT1 cells. These genes
are: DNM3 (dynamin 3), SNX22 (sorting nexin 22),
ATP6AP1 (ATPase, H+ Transporting, Lysosomal Accessory
Protein 1), HRBL (HIV-Rev binding protein Like), IDH3G
(Isocitrate dehydrogenase), HSP90B1 (Heat shock protein
90 kDa beta member 1), EPS15 (Epidermal Growth Factor
Receptor Pathway Substrate 15). Four genes (DNM3,
EPS15, ATP6AP1, IDH3G) out of seven were also found
to significantly reduce HIV-1 replication upon knock-down.
Results
Genome-wide shRNA screening
We performed a shRNA genome-wide screening to dis-
cover cellular factors involved in CD4 down-regulation
in Nef-expressing cells. CD4 positive HeLa cells were
transduced with a pooled commercial lentiviral vector
library (System Biosciences) encoding shRNAs targeting
the whole genome under a puromycin resistance selection
marker. The library contained 200,000 shRNA sequences
targeting around 47,000 human transcripts. Viral titer was
adjusted to a multiplicity of infection of 0.3. In this way
efficiently transduced cells, selected by puromycin resist-
ance, were expected to express only one shRNA sequence.
These selected cells were subsequently transduced with a
retrovirus encoding Nef and eGFP as a reporter gene [17].
The expression of Nef decreases cell surface CD4 levels,
but not in the few cells that express a shRNA blocking the
expression of a gene important for CD4 down-regulation.
Therefore, eGFP positive cells (expressing Nef) with high
surface CD4 levels (Nef(eGFP)+CD4hi) were sorted with
flow cytometry, as well as the population of cells expressing
Nef and expressing low CD4 levels (Nef(eGFP)+CD4low).
The expressed shRNA sequences were amplified with bio-
tinylated primers from the cDNA of these two populations,
and PCR products were hybridized to a microarray compat-
ible with the lentiviral library. The shRNA sequences that
were over-represented in Nef(eGFP)+CD4hi cells by at least
two-fold compared to the Nef(eGFP)+CD4low population
were selected using criteria as the magnitude of the ratio,
the reproducibility in 4 independent genome-wide screen-
ings, and their biological function (Figure 1). Among the
gene products targeted by the shRNA sequences over-
represented in the Nef+CD4hi cells, several known Nef
co-factors like AP2A2 (Adaptor protein 2, subunit alpha),
clathrin chains CLTB (Clathrin, light chain) and CLTC1
(Clathrin, heavy chain like 1) were found, which can be
considered as a proof of validity of the screening approach.
We obtained a shortlist of 55 genes, most of them involved
in different stages of the endocytic, recycling, Trans Golgi
Network (TGN) and lysosomal degradation pathways. To
this, 20 genes (mainly other members of the families of the
Figure 1 Schematic representation of the genome-wide shRNA screening workflow. HeLa CD4++ cells were transduced with a pooled
shRNA lentiviral library. Productively transduced cells were selected with puromycin and transduced with a retroviral vector for the expression of
HIV-1 Nef and eGFP as a reporter gene. Cells that maintained high CD4 surface levels despite the expression of Nef (Nef(eGFP)+CD4hi, red box)
and the Nef(eGFP)+CD4low population (green box) were sorted by FACS. The shRNA hairpins present in the cDNA obtained from the two sorted
populations were amplified by nested PCR with biotinylated primers. The samples obtained were hybridized on different Affymetrix U133 v2-plus
microarrays and the results compared. shRNA sequences enriched in the Nef(eGFP)+CD4hi cells were selected and further analyzed with pathway
analysis tools to obtain a final list of 55 genes to be further validated together with 20 genes selected from literature.
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were added (see Additional file 1). The final set of 75 genes
was used in the further selection, validation and confir-
mation steps.
Biological validation of the hits
To confirm the biological relevance of the selected gene
candidates, we used an independent validation strategy
using different shRNA sequences (Mission RNAi consor-
tium) to target the genes identified during the screening.
For each of the selected genes, we individually evaluated
2 to 5 lentiviral clones, each expressing different shRNA
sequences to target the gene transcript (depending on
the validation status and availability by the supplier).
The validation set-up involved two different approaches:
the first approach (validation 1) was a confirmation of
the hits in HeLa CD4++ using Nef as an inducer of CD4
down-modulation. Screening hits confirmed in HeLa
cells were subsequently investigated in a more relevant
system (validation 2): SupT1 T cells infected with HIV-1
engineered to express an eGFP reporter gene (Table 1).
Our final interest is primarily in host proteins that areimportant for CD4 trafficking in HIV-1-infected cells,
but in epithelial cells such as HeLa cells, CD4 trafficking
might differ in some aspects from that in T cells, the
main targets of HIV-1 [18]. In validation 1, we confirmed
that knock-down of 20 genes out of 75 selected hits
affected CD4 down-regulation (see Figure 2). These genes
were further evaluated in validation 2. These 20 selected
genes are briefly described in Additional file 2. In valid-
ation 2, cell surface expression of CD4 was analyzed two,
four and seven days after HIV infection of SupT1 cells ex-
pressing shRNA targeting one of these 20 genes. For this,
we used an HIV NL4-3 construct expressing all the HIV
genes and a GFP marker gene expressed in frame with
Nef, separated through an IRES sequence. The residual
CD4 expression in the HIV-infected fraction (eGFP+)
compared to uninfected cells in the same culture (eGFP−)
was calculated as described in Methods. Seven genes were
found to significantly contribute to CD4 down-regulation
in HIV-infected SupT1 (Figure 3A). These genes are:
DNM3 (dynamin 3; 1.7 fold increase of CD4 residual
expression compared to non-targeting shRNA-expressing
cells), SNX22 (sorting nexin 22; 1.5 fold), HRBL (HIV-Rev
Table 1 Experimental setup overview for the validation of the hits obtained from the genome-wide shRNA screening
Genome-wide screening Validation 1 Validation 2
Cells HeLa CD4++ cl1022 HeLa CD4++ cl1022 SupT1
Format Pooled shRNA library Single shRNA Single shRNA
shRNA plasmid pSIF H1 SBI (System Biosciences) pLKO.1 (MISSION® Sigma Aldrich) pLKO.1 (MISSION® Sigma Aldrich)
CD4 down-modulation inducer LZRS-NA7 Nef-IRES-eGFP LZRS-NA7 Nef-IRES-eGFP HIV-1 NL4.3 eGFP
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genase; 1.9 fold), HSP90B1 (Heat shock protein 90 kDa
beta member 1; 1.3 fold), EPS15 (Epidermal Growth Factor
Receptor Pathway Substrate 15; 4 fold) and ATP6AP1
(ATPase, H+ Transporting, Lysosomal Accessory Protein 1;
1.25 fold). The knock-down efficiencies at mRNA level
were determined via qPCR for the selected shRNA clones
(see Additional file 3). To investigate whether the effects
observed were Nef-dependent we performed two additional
sets of experiments, using different viruses and vectors.
In the first, we compared CD4 down-modulation, either
induced by wild type reporter virus (HIV-1 NL4-3 IRES-
EGFP) or by a vpu -deleted derivative virus (HIV-1 NL4-3
IRES-EGFP, dVpu) in SupT1 cells knocked-down for the
target genes. The residual CD4 expression in the HIV-
infected cells was calculated as described above. The fold
increase of CD4-expression in cells knocked down for the
target genes relative to the control non-targeting shRNA-
expressing cells was comparable between WT and dVpu
viruses (Figure 3C), suggesting little contribution of these
factors to Vpu-mediated CD4 down-regulation.Figure 2 Results of validation 1: CD4 residual expression in HeLa CD4
genes. Bar graph shows the residual CD4 expression in HeLa CD4++ expre
Nef retroviral construct. The values are representative of two independent
among the ones tested. The gray bar indicates the value obtained in cellsIn the second set of experiments, we investigated CD4
down-regulation when Nef alone (thus not the full viral
genome) was expressed in SupT1 cells by transduction
with a retroviral vector, similar to the approach used in
HeLa CD4++ cells for the shRNA genome-wide screen-
ing and subsequent validation. Remarkably, only cells
knocked down for HRBL, EPS15 and HSP90B1 were
found to significantly express higher CD4 surface levels
than the non-targeting shRNA control cells. The knock-
down of the other gene hits, IDH3G, SNX22, DNM3
caused only a minor, non-significant increase of CD4
surface expression and the knock-down of ATP6AP1
was found to leave the CD4 levels unaffected in this
set-up (Figure 3D).
Effect of the down-regulation of the selected gene
products on HIV-1 replication
It has been previously shown that Nef-mediated CD4
down-regulation correlates with the ability of the virus
to efficiently replicate in CD4+ T lymphocytes [19]. There-
fore, we wanted to evaluate whether the rescue of surface++ expressing Nef and the shRNAs targeting the selected 20
ssing the shRNAs for the knock-down of the 20 selected hits and the
confirmation experiments and for the shRNA clone with most activity
transduced with the non-targeting scrambled shRNA control.
Figure 3 Effect of the knock-down of the selected genes on CD4 expression in HIV-1-infected SupT1 cells. A. The bar graph shows the
residual CD4 surface expression levels in HIV-1-infected (eGFP+) SupT1 cells (calculated as described in Methods) normalized to the non-targeting
shRNA scrambled control. Error bars represent standard deviation between 7 to 17 independent experiments. The values are representative of the
shRNA clone with most activity among the ones tested. P values: ***p≤ 0.0004; **p≤ 0.0099; *p ≤ 0.038. B. Flow cytometry dot plots showing the
CD4 surface levels in HIV-1-infected cells in a representative experiment. eGFP is the reporter for HIV-1 infection, while CD4 levels are measured
by surface staining with an anti-CD4 monoclonal antibody conjugated to APC. The numbers on the FACS plots indicate the mean fluorescence
intensity of CD4 gated on the upper right and lower right quadrants. C. The bar graph shows the residual CD4 surface expression levels in shRNA
expressing SupT1 cells normalized to the non-targeting shRNA scrambled controls (calculated as described in Methods), infected with the wild
type (black bars, indicated as HIV-1 WT) and the dVpu HIV-1 NL4-3 IRES-EGFP (grey bars, indicated as HIV-1 dVpu). Error bars represent standard
deviation between 3 independent experiments. D. The bar graph shows the residual CD4 surface expression levels (calculated as described in
Methods) in SupT1 cells transduced by a retroviral vector to express Nef, normalized to the non-targeting shRNA scrambled control. Error bars
represent standard deviation between 7 to 16 independent experiments. P values: ***p≤ 0.0006 ; **p≤ 0.0011.
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shRNAs was inhibiting HIV-1 replication. To do so, we
evaluated HIV-1 infection levels in SupT1 cells expressing
the selected shRNAs two, four and seven days post-
infection. By comparing infection levels in these cells with
those of cells expressing the non-targeting scrambled
shRNA control we found that the knock-down of four
out of seven genes (ATP6AP1, IDH3G, DNM3 and
EPS15) reduced HIV-1 replication significantly, as shown
in Figure 4A, without affecting the viability of the cells
(data not shown). Despite increasing CD4 surface expres-
sion levels in infected cells, the knock-down of HRBL,
HSP90B1 and SNX22 did not have a significant effect
on HIV-1 replication (Figure 4B). Therefore, in ourexperiments, the rescue of CD4 expression levels does not
strictly correlate with a decrease in HIV-1 replication.
Discussion
The importance of HIV-mediated CD4 down-modulation
for the viral replication and the disease progression
[2-4,20] renders research on this topic of vital importance
to better understand the virus and to identify host factors
involved in the process. We were especially interested in
exploring the cellular pathways that are exploited by the
virus to achieve CD4 down-modulation. In order to do so,
we screened for host partners involved in HIV-mediated
CD4 down-regulation using a genome-wide screening
approach in CD4-positive HeLa cells transduced with a
Figure 4 Knock-down of some genes involved in CD4 down-regulation decreases replication of HIV-1 in SupT1 cells. A. Knock-down of
four genes involved in CD4 down-regulation (EPS15, DNM3, ATP6AP1, IDH3G) decreases HIV-1 replication: graphs show levels of HIV-1 infection at
different time points (2, 4 and 7 days post-infection), as measured by the percentage of eGFP expressing cells in the population. The grey lines
represent HIV-1 replication in the negative control (cells expressing the non-targeting shRNA), the black line represents cells expressing the target
shRNAs. Bar graphs represent the standard deviations for 5 to 6 independent experiments (p values: *p ≤ 0.03, **p ≤0.008). B. Knock-down of
HRBL, SNX22, HSP90B1 does not affect HIV-1 replication: graph represent levels of HIV-1 infection as described for Figure 4A.
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inducer of CD4 down-modulation [17]. We found several
genes known to be involved in CD4 down-regulation by
Nef, such as AP-2 [8,9,21] via clathrin-mediated endocy-
tosis [22], illustrating the validity of our genome-wide
screening approach. However, others like β-COP were not
identified. Such false negatives are inherent to a RNAi
screening effort, and can be attributed to the cellular
model used, insufficient knock-down or functional com-
pensation by other proteins. Also false positive hits or lessrelevant host factors might be found, e.g. due to off-target
effects of shRNA [23]. To minimize false positives, we
chose to validate our findings not only with a different
shRNA systems and independent shRNA sequences (indi-
vidual Mission pLKO.1 vectors opposed to pooled System
Biosciences SIF H1 vectors) but also in a different, more
relevant cell type and infection model (HIV-1 infected T
cells opposed to Nef expressing epithelial cells). Epithelial
cell lines have already been successfully used in genome-
wide screening studies looking for HIV-1 co-factors or
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HIV infection. The HeLa CD4++ clone is expressing the
receptor artificially by stable transfection and therefore
might have a different CD4 expression equilibrium [18].
Furthermore, the HIV-1 Nef protein is only one determin-
ant of the effect of the virus on the CD4 expression
profiles. Moreover, as highlighted in the review of Houzet
and Jeang [16], a thorough validation of genome-wide
screening results is necessary. Finally, validation of screen-
ing hits with different shRNA systems and in different cell
types contributes to exclude off-target effects. At the end
of these stringent validation rounds we were able to iden-
tify seven genes which significantly contributed to CD4
down-regulation in HIV-infected SupT1 cells: DNM3,
SNX22, HRBL, IDH3G, HSP90B1, EPS15 and ATP6AP1.
Additionally, we investigated whether the effects observed
in HIV-1 infected SupT1 cells were selectively dependent
on Nef. To do so, we compared CD4 levels in cells
infected with either a wild type reporter HIV-1 or a HIV-1
carrying a deletion in the vpu gene. The fold increase
in CD4-expression on cells in which the target genes
were knocked-down, relative to the non-targeting shRNA-
expressing cells, was comparable for both viruses,
suggesting that these hit genes are not important for
Vpu-mediated CD4 down-regulation. To investigate Nef
specifically, we evaluated CD4 expression levels in cells
expressing both the shRNAs targeting the gene hits and
Nef. HRBL, EPS15 and HSP90B1 knock-down increased
CD4 levels significantly in this experimental set-up, while
the knock-down of IDH3G, SNX22 and DNM3 affected
CD4 expression levels only in a minor, non-significant
manner. The difference between these results and the
ones obtained when Nef was expressed in HeLa CD4++
could be due to differences in CD4 endocytosis and
trafficking in epithelial cells artificially expressing the CD4
receptor [18]. Compared to infected cells, Nef expression
levels might be different, and additional contributions of
other HIV proteins like Env to CD4 down-regulation are
missing when Nef is expressed alone.
In general the knock-down of these genes does not
rescue CD4 levels completely to levels in non-infected
cells. The incomplete rescue could be due to partial
knock-down of the target genes, as residual expression is
still observed via mRNA quantification by qPCR. Fur-
thermore, pathway redundancy might compensate in
part for the function of a knocked-down gene candidate
involved in CD4 trafficking. Not surprisingly, most of the
identified factors are known to be involved in endocytic
events at the cell surface or at the level of early endocytic
sorting pathways. It has been shown previously that
dynamin 2 (DNM2) is required for Nef-mediated CD4
down-regulation [9] but the role of DNM3 has not been
investigated before. DNM3, a member of the dynamin
protein family, could therefore have an analogous roleas a co-factor for HIV-1-mediated CD4 down-regulation.
EPS15 is a clathrin adaptor, interacting with AP-2 during
vesicle formation. The knock-down of EPS15 is known to
strongly reduce Nef- and PMA-dependent CD4 down-
modulation [8] and our study is the first to evaluate the
role of EPS15 on CD4 down-regulation in productively
HIV-1-infected cells. HRBL is a poorly characterized pro-
tein, but shares similarity with another Rev binding pro-
tein, HRB (HIV Rev Binding protein), which is able to
affect endocytosis of transferrin in an EPS15-dependent
manner and has been found in the AP-2 interactome [24].
Our findings suggest a role for HRBL in clathrin mediated
endocytosis by demonstrating its role in HIV-mediated
CD4 down-regulation and propose it to be an interesting
candidate for further studies together with its binding
partner EPS15. The finding that both EPS15 and HRBL
mediate CD4 down-regulation in a Nef-specific manner
makes these two genes especially intriguing for further
mechanistic investigation. SNX22 is located further in the
endocytic pathway, as sorting nexins are involved in early
endosomal sorting events. More mechanistic investiga-
tion is needed on the role of SNX22 on CD4 down-
modulation as its structure and function have been poorly
studied so far [25]. ATP6AP1, a V-ATPase, is involved in
the acidification of endocytic compartments and could
therefore play a role in endocytic sorting or lysosomal
degradation of the internalized receptor. It has also been
previously shown that V-ATPases interacts with Nef
and AP-2 [26]. However, the contribution of ATP6AP1
to HIV-1 mediated down-regulation of CD4 that was
observed with one HIV-1 construct (NLENG1-IRES)
could not be confirmed in experiments with NL4-3 IRES-
EGFP HIV. The role of HSP90B1 and IDH3G in CD4
endocytosis is less clear, as these proteins are not known
to be associated with the endocytic and trafficking path-
way, although HSP90B1, a chaperone involved in the mat-
uration of proteins in the ER [27], could have an effect on
the folding of viral or cellular proteins important for this
process. Moreover, HSP90 has been found to promote
HIV-1 life cycle in several ways (e.g. by activating the
P-TEFb complex necessary for HIV-1 transcription or
by enhancing replication in hypothermic conditions)
[28]. For IDH3G no role in endocytosis has been shown.
Nevertheless, this gene could be very important for HIV-1
replication as it is a key enzyme of the citric acid cycle
and necessary for the energetic metabolism of the cell.
A transcriptome analysis highlighted the citric acid
cycle as one of the pathways enriched in CD4+ and
CD8+ cells from HIV-1-infected patients [29]. It has
been shown previously that CD4 down-regulation by
HIV-1 Nef promotes efficient viral replication [19]. There-
fore, we wanted to investigate whether the increased
CD4 expression levels in the target shRNA-expressing
cells could hamper HIV-1 replication. We found that
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and ATP6AP1) significantly inhibits HIV-1 replication,
especially at later time-points (from four to seven days
post-infection). We didn’t observe a strict correlation
between CD4 down-regulation and HIV-1 replication,
as the knock-down of HRBL, SNX22 and HSP90B1 in-
creased CD4 surface expression, but did not affect
HIV-1 replication significantly. It could be speculated
that the effect on replication by DNM3, IDH3G, EPS15,
and ATP6AP1 knock-down are due to functions of
these genes independent of HIV-mediated CD4 down-
regulation. On the other hand, the knock-down of the
three genes with the largest effect on CD4 expression
in infected cells, DNM3, IDH3G and EPS15, also had
the most detrimental effect on HIV-1 replication. Fol-
lowing this, we hypothesize that the CD4 levels in cells
expressing shHRBL, shHSP90B1 and shSNX22 are still
sufficiently low to ensure an efficient HIV-1 replication,
while the negative effect on HIV-1 replication observed in
shATP6AP1 cells could be due to other functions of
this protein and be not linked to CD4 expression.
In a study by Daecke J. et al. [30], the expression of a
dominant negative mutant of EPS15 greatly reduced
HIV-1 entry by endocytosis in HeLa cells. Doria et al.
[31] have also shown that EPS15 could be involved in
replication at the level of the Rev export pathway in a
synergistic manner with the HIV-1 Rev Binding proteins
HRB and HRBL. Considering our results and the data
published in literature, it will be interesting to further
evaluate the effects of EPS15 and DNM3 on HIV-1 entry
and infectivity and the mechanisms involved. Moreover,
it will be interesting to evaluate the effects of EPS15 and
DNM3 on later replication events (e.g. virion budding).
Conclusions
In conclusion, we propose a novel genome-wide screen-
ing set-up for the study of cellular factors involved in
the endocytosis of surface proteins and receptors. This
approach could be useful for broader applications, other
than the study of HIV-1-mediated CD4 down-modulation.
Our results identify seven genes, DNM3, SNX22, HRBL,
IDH3G, HSP90B1, EPS15, ATP6AP1 as co-factors for
HIV-1-mediated CD4 down-regulation in T cells. The
knock-down of EPS15, DNM3, ATP6AP1 and IDH3G also
significantly reduces HIV-1 replication in T cells, although
more experimental efforts are required to investigate
whether the decreased HIV-1 replication can be attributed
to changed CD4 expression levels in infected cells or are
due to independent functions of these proteins. These
findings give insights in the HIV-1-mediated CD4 down-
regulation at the level of the plasma membrane and early
endosomes and open future research possibilities for the
elucidation of the HIV-1-mediated CD4 down-modulation
pathway.Methods
Cell cultures
SupT1, 293 T and Phoenix cell lines were cultured as
described previously [9], HeLa CD4++ cl1022 (AIDS
Research and Reference Reagent Program, National
Institutes of Health, Bethesda, MD) cells were cultured
in Iscove modified Dulbecco medium (IMDM, Life Tech-
nologies, Carlsbad, CA) supplemented with 2 mM L-
glutamine 1% (Life Technologies), 10% (vol/vol) heat
inactivated fetal calf serum (Hyclone Perbio, Thermo
Scientific, Rockford, IL), 100 U/mL penicillin, 100 μg/mL
streptomycin (Life Technologies) and geneticin 10 μL/mL
(G418 Sulfate, Life Technologies) at 37°C in a humidified
atmosphere containing 7% (vol/vol) CO2 in air.
Plasmids and vectors
The GeneNetTM shRNA Lentiviral Library, the control
vectors pSIF1-H1 · shLuc-copGFP, pSIF1-H1 · puro-shRNA,
pSIF1-H1 · shLuc-puro and the packaging plasmids pFIV-
34N and vesicular stomatitis virus envelope pVSV-G were
all purchased from System Biosciences (Mountain View,
CA). The retroviral vector LZRS-NA7-IRES-eGFP encod-
ing Nef (HIV-1 subtype B NA7 strain) and eGFP was
described before [9,16]. The shRNA clones pLKO.1-puro
(TRC1 and TRC1.5, 2 to 5 different pLKO.1-shRNA-puro
clones with different shRNA sequences per gene depending
on availability and validation status) were purchased as bac-
terial glycerol stocks from Sigma Aldrich (St. Louis, MO).
MISSION® Lentiviral Packaging Mix containing lentiviral
packaging plasmid and the VSV envelope plasmid were
purchased as a pre-made mix from Sigma Aldrich. As con-
trol, a pLKO.1 vector encoding a non-targeting scrambled
shRNA (a shRNA sequence not targeting any known gene)
and puromycin resistance as a marker gene was used (non-
targeting-puro shRNA, SHC002, Sigma Aldrich). Plasmid
containing cloned proviral DNA of HIV-1 NLENG1-IRES
(replication competent HIV NL4-3 virus, characterized by
complete HIV genome engineered to express eGFP as part
of a bi-cistronic eGFP-IRES-Nef mRNA) was kindly pro-
vided by Dr. D.N. Levy, New York University college of
Dentistry, New York, NY [32,33]. For the experiments
comparing effects on CD4 expression of WT and Vpu-
deleted HIV-1, HIV-1 NL4-3 proviral constructs either WT
or deleted and engineered to express eGFP as part of a
bi-cistronic Nef-IRES-eGFP mRNA were kindly donated
by Prof. Dr. Frank Kirchhoff and described in [6].
Production of retroviral and lentiviral vectors and
replication-competent HIV-1 reporter virus
The Phoenix-Amphotropic packaging cell line was trans-
fected with the different retroviral constructs as described
previously [9,17]. For lentiviral vector production from
pLKO.1 vectors, 293 T cells were seeded 24 h before
transfection in 96-wells plates at a density of 13,000 cells
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per well. Transfection of the pLKO.1 clones was per-
formed after mixing with MISSION® Lentiviral Packaging
Mix using FuGENE® HD (Promega, Madison, WI) follow-
ing the protocol recommended by the manufacturer. The
supernatant was harvested 48 and 72 h after transfection
and stored at -80°C until use for transduction of the se-
lected cell lines. Lentivirus production from pSIF1 vectors,
was performed using the envelope pVSV-G and packaging
pFIV-34 N plasmids (System Biosciences) as described be-
fore [9]. Replication-competent HIV-1 virus was produced
by transfection (JetPei®, Polyplus, Sélestat, France), accord-
ing to manufacturer’s instructions, of 293 T cells (seeded
24 hours before transfection at a density of 750,000) with
the pNL4-3 proviral construct NLENG1-IRES [32,33].
Viral supernatant was harvested 48 hours after transfec-
tion, spun at 900 g for 10 min, to clarify the supernatant
from remaining cells and stored at -80°C. The titer of the
viral supernatants was measured by quantification of re-
verse transcriptase activity via real-time PCR as described
in [34] and expressed as equivalent p24.
Monoclonal antibodies, flow cytometry, and cell isolation
methods
The monoclonal antibodies used were allophycocyanin
(APC)-conjugated human anti-CD4 (Miltenyi Biotec,
Leiden, The Netherlands) and phycoerythrin (PE)-conju-
gated anti-CD4 antibody (Becton Dickinson, Franklin
Lakes, NJ). The stained cells were analyzed for CD4
expression on a MACSQuant flow cytometer (Miltenyi Bio-
tec) or FACS Calibur flow cytometer (Becton Dickinson).
GFP+ HeLa CD4++ cl1022 cells were sorted with FACS
Aria cell sorter (Becton Dickinson) after staining with PE-
conjugated anti-CD4 antibody. The purity of the isolated
cell fractions was analyzed with FACS Calibur (Becton
Dickinson). Analysis of flow cytometry data was per-
formed with MACSQuantifyTM version 2.5 and Flowing
software version 2.5.1.
Genome-wide shRNA screening
Hela-CD4++ cl1022 cells were transduced either with
the pooled shRNA library or the control lentiviral vector
H1 · siLuc-copGFP (System Biosciences). Viral titer was
adjusted to a multiplicity of infection of 0.3. Efficiently
transduced cells were selected with puromycin (0.5 μg/
mL, Sigma Aldrich) and transduced with the Nef-
expressing retroviral vector. Cells maintaining high CD4
expression despite expression of Nef (Nef(eGFP)+CD4hi)
were sorted by FACS as well as the population express-
ing Nef and low levels of CD4 (Nef(eGFP)+CD4low).
To identify the shRNA sequences enriched in Nef
(eGFP)+CD4hi cells, total RNA was extracted from this
cell population and from the Nef(eGFP)+CD4low refer-
ence population. Reverse transcription was performedstarting from 10 μg of total RNA following manufac-
turer’s instructions (System Biosciences). and shRNA se-
quences were amplified with a nested PCR using
biotinylated primers (System Biosciences) following the
manufacturer instructions. These amplified shRNA frag-
ments were then digested with lambda exonuclease to
remove the non-biotinylated strand, following manufac-
turer instructions (System Biosciences) and hybridized
on Affymetrix microarray U133 v2-plus (hybridization
performed by ServiceXS, Leiden, Netherlands). The pro-
cedure was performed for both the Nef(eGFP)+CD4hi
and Nef(eGFP)+CD4low populations, that were compared
side by side per screening experiment, and repeated
for four independent screening experiments. Data
summarization from the raw intensity signals obtained
from the microarray hybridization was performed using
the software Affymetrix Expression Console v1.1 with
MAS5 algorythm [35]. The signal intensities of the Nef
(eGFP)+CD4hi cells were compared to the signal inten-
sities of Nef(eGFP)+CD4low cells, resulting in the selection
of the genes over-represented in the Nef(eGFP)+CD4hi
sorted cells with at least two-fold enrichment compared
to the Nef(eGFP)+CD4low cells. Among these, only inten-
sities with present (P) or marginal (M) detection call, a
measure of the p-value implemented in the Mas5 algor-
ythm, were selected. From the four screening experiments
we selected a shortlist of 55 genes, to which we added 20
selected from literature. The final list of the 75 selected
genes is shown in Additional file 1. We selected genes
appearing in multiple screenings or in one screening
but with a high Nef(eGFP)+CD4hi/Nef(eGFP)+CD4low
ratio, followed by further filtration for biological rele-
vance using the pathway analysis tools DAVID (Data-
base for Annotation, Visualization and Integrated
Discovery, [36,37]) and IPA (Ingenuity Pathway Ana-
lysis, Ingenuity Systems® [38]).
Viral gene transfer and HIV-1 infection
For retroviral transduction, HeLa CD4++ cl1022 or
SupT1 cells were mixed with retroviral vector super-
natant and Dotap (0.2 μg/mL, Roche Diagnostics) and
spun for 90 min (950 g, 32°C) as described before [9].
For lentiviral transductions, cells were mixed with the
lentiviral vector and spun (30 min, 950 g, 32°C) in the
presence of polybrene (8 μg/mL; Sigma-Aldrich). For the
cells transduced with the pLKO.1-shRNA-puromycin
lentiviruses, puromycin selection was started three days
after transduction (1 μg/mL puromycin for SupT1 cells
and 0.5 μg/mL for HeLa CD4++ cells, Sigma Aldrich).
HIV-1 infection of SupT1 cells was performed in 96-well
plates using 50,000 cells/well and HIV-1 virus (20 ng
p24/well were used for the NLENG1-IRES NL4-3 virus,
40 ng p24/well for HIV-1 NL4-3 IRES-EGFP WT and
50 ng p24/well for HIV-1 NL4-3 IRES-EGFP dVpu) in a
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950 g at 32°C. NLENG1-IRES NL4-3 was used as such
to correspond to a multiplicity of infection (MOI) of 0.01,
to have in every independent experiment on average
10% infected cells two days post-infection, 28% infected
cells four days post-infection and 90-95% seven days
post-infection. The cells infected with HIV-1 NL4-3
IRES-EGFP viruses were analyzed four days post-infection,
when the percentage of infected cells was 6% (WT) and 7%
(dVpu).
In the experiments requiring both lentiviral (pLKO.1-
shRNA-puro) and retroviral (LZRS-NA7-IRES-eGFP)
vector transduction or infection with a replication com-
petent HIV-1 virus, the following protocol was applied:
cells were transduced with the shRNA lentiviruses and
efficiently transduced cells were selected with puromycin
as described above. Three days after the start of selection,
cells were transduced with the Nef-encoding retrovirus or
infected with HIV-1. The degree of CD4 receptor modula-
tion was evaluated by flow cytometry 3 days after trans-
duction or 2, 4 and 7 days after infection for the
NLENG1-IRES NL4-3 virus; 2 and 4 days post-infection
for HIV-1 NL4-3 IRES-EGFP. The residual CD4 surface
expression was calculated as described previously [9].
Primers
The primers used for the amplification and biotinylation
of the shRNA hairpins Fwd-GNF/Rev-GNF and NFwd-
Bio/NRev-GNF were included in the shRNA Lentiviral
Library kit (System Biosciences) and the PCR/nested PCR
were performed following the manufacturer’s instructions.
Primers used for qPCR were: HRBL Fwd (sense) 5’-
CCC CCT CGT GTC AAG TC-3’, HRBL Rev (antisense)
5’-CGG CAA ACC TCA TTT CCA CG-3’, SNX22 Fwd
(sense) 5’-TGG AAG TTC ACA TCC CGT CG-3’,
SNX22 Rev (antisense) 5’-CTC GGA ACA CCA TGT
GGC TT-3’, DNM3 Fwd (sense) 5’-TGG CAT GTG
ATT CCC AGG AG-3’, DNM3 Rev (antisense) 5’-TCC
ATT CTC ATC ATT TTC AGC TAC A-3’, EPS15
Fwd (sense) 5’-TTG CAT TGT TTG CTG GTC TTC
T-3’, EPS15 Rev (antisense) 5’-TGA AGA TCC TGA
ACC TCA CTT G-3’, ATP6AP1 Fwd (sense) 5’-CGT
ACA ACC AGT GGG AG-3’, ATP6AP1 Rev (anti-
sense) 5’-TCA GTG AGA GCC TGG CAA AG-3’; UBC
Fwd (sense) 5’- ATTTGGGTCGCGGTTCTTG -3’, UBC
Rev (antisense) 5’- TGCCTTGACATTCTCGATGGT-3’,
YWHAZ Fwd (sense) 5’-CTTTTGGTACATTGTGGCT
TC AA -3’, YWHAZ Rev (antisense) 5’-CCGCCAGGA
CAAACCAGTAT -3’, ACTB Fwd (sense) 5’-TGACC
CAGATCATGTTTGAGA -3’, ACTB Rev (antisense)
5’AGAGGCGTACAGGGATAG GA-3’. These were
designed with PrimerBLAST [39] and checked for
homo-dimers, hetero-dimers and hairpin formation
with IDT OligoAnalyzer [40] (http://eu.idtdna.com/analyzer/applications/oligoanalyzer). All primers were
purchased from IDT (Integrated DNA Technologies,
Europe Branch, Leuven, Belgium). amplification efficiency
was evaluated using a serial cDNA dilution series as
standard curve and efficiencies were found to be 90-110%
for all primer paires. Primers for IDH3G and HSP90B1
were purchased as PrimePCR Sybr Green assays from
Biorad (Nazareth, Belgium).Quantitative real-time PCR
Quantitative real-time PCR (qPCR) was used to evaluate
the residual expression levels of target genes EPS15,
HSP90B1, IDH3G, HRBL, ATP6AP1, DNM3, SNX22 in
SupT1 cells expressing the shRNA clones. Reverse tran-
scription was performed with SuperScript® III reverse
transcriptase and random primers (Life Technologies),
starting from 1 μg of total RNA extracted from the fro-
zen lysate of the transduced cells (RNeasy kit, Qiagen,
Venlo, The Netherlands) and treated with DNAse I (Life
technologies) following the manufacturer’s instructions.
All qPCR reactions were performed using the LightCycler®
480 SYBR Green I Master mix (Roche Applied Science,
Vilvoorde, Belgium) in a final volume of 15 μl on the
LightCycler® 480 (Roche Applied Science). The primers
designed in house with PrimerBlast and purchased from
IDT were used at a final concentration of 300 nM. The
thermal cycling conditions were 95°C for 10 min, followed
by 45 cycles at 95°C for 10 s, 60°C for 30 s and 72°C
for 30 s. The relative expression levels of the target
genes were calculated using the qBasePLUS software
2.0 (Biogazelle, Zwijnaarde, Belgium) with UBC (ubi-
quitin C), ACTB (beta-actin) and YWHAZ (tyrosine
3-monooxygenase/tryptophan 5-monooxygenase acti-
vation protein) as reference genes, selected with the
geNorm algorithm based on their expression stabilities
[41]. The expression of the genes relative to the non-
targeting scrambled control were calculated with the
qBase software (Biogazelle, Belgium).Selected shRNA clones
The shRNA clones targeting the selected gene candi-
dates whose knock-down was found to inhibit HIV-1-
mediated CD4 down-regulation and/or HIV-1 replication
in SupT1 are (The RNAi Consortium Number (TRCN)
and NCBI RefSeq transcript number are indicated):
EPS15 [TRCN0000060225; NCBI RefSeq: NM_001981],
HRBL [TRCN0000011062; NCBI RefSeq: NM_030662],
ATP6AP1 [TRCN0000117834; NCBI RefSeq: NM_178509],
SNX22 [TRCN0000006650; NCBI RefSeq: NM_004945],
HSP90B1 [TRCN0000029425; NCBI RefSeq: NM_003299],
IDH3G [TRCN0000027281; NCBI RefSeq: NM_174869],
DNM3 [TRCN0000051404; NCBI RefSeq: NM_015569].
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Wilcoxon paired test was performed using GraphPad
Prism version 5.00 for Windows (GraphPad Software,
San Diego California USA).Additional files
Additional file 1: Summary of the 75 hits chosen after the genome-
wide shRNA screening in HeLa CD4++. The table shows gene symbols
and the origin of the chosen hit (screening or literature). When the hit
originates from the screening, also the frequency in four independent
screenings and the Nef(eGFP)+CD4hi/ Nef(eGFP)+CD4low ratio is listed. Some
screening hits are identified twice in the same array by different probes.
Additional file 2: Description of the 20 preliminary hits from
validation 1. The table describes the 20 hits obtained from validation 1
in HeLa CD4++ cells expressing Nef with the official gene symbol and
name and a brief functional description.
Additional file 3:mRNA expression after shRNA-mediated knock-down
for the genes selected in validation 2. The bar graph shows residual
mRNA expression of the indicated target genes after shRNA-mediated
knock-down in SupT1 cells, relative to the levels in SupT1 cells transduced
with the non-targeting scrambled shRNA control (grey bar) as determined
by qPCR. The error bars represent the standard deviation for two to five
independent experiments.Competing interests
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